Mycozyl AL
openFDA label record#
This page contains supplementary openFDA label data. For the canonical label presentation, use the corresponding DailyMed Structured Product Label.
Verified complete openFDA source JSON
- Brand name
- Mycozyl AL
- Generic name
- TOLNAFTATE
- Manufacturer
- PURETEK CORPORATION
- Product type
- HUMAN PRESCRIPTION DRUG
- SPL set ID
- 07edd043-4ac4-b2de-e063-6394a90af25d
- SPL ID
- 07edd043-4ac5-b2de-e063-6394a90af25d
- Version
- 1
- Effective date
- 2023-10-17
- Source export date
- 2026-09-28
- Source partition
- 1
- Source file
- https://download.open.fda.gov/drug/label/drug-label-0001-of-0014.json.zip
- Source object key
- raw/openfda/drug-label/2026-09-28/9c7783846d422acb0c9e59457606951c785a7d28cc631c8cc4839d0dc7c55f39/drug-label-0001-of-0014.json.zip
- Source manifest SHA-256
- cd2e66336a5cd2223fa3995098fdbdb84c6a7ee5c0a4addb236ccb22dd1e6887
- Import run
- 20260929T050834Z
- Imported at
- 2026-09-29 05:14:04
| Harmonized routes |
|---|
| TOPICAL |
Harmonized identifier links#
Every typed identifier imported from the complete openFDA harmonization object is paginated here; values are not reduced to a first match.
| Type | Scope | Identifier | Source field |
|---|---|---|---|
| brand name | Mycozyl AL | openfda.brand_name | |
| generic name | TOLNAFTATE | openfda.generic_name | |
| manufacturer name | PURETEK CORPORATION | openfda.manufacturer_name | |
| ndc | package | 59088-443-01 | openfda.package_ndc |
| ndc | product | 59088-443 | openfda.product_ndc |
| ndc11 | package | 59088044301 | derived:openfda.package_ndc |
| rxcui | 313423 | openfda.rxcui | |
| spl id | 07edd043-4ac5-b2de-e063-6394a90af25d | id | |
| spl set id | 07edd043-4ac4-b2de-e063-6394a90af25d | set_id | |
| unii | 06KB629TKV | openfda.unii |
Warnings cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
WARNINGS: For External Use Only. Not For Ophthalmic Use
Adverse reactions cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
adverse reactions
ADVERSE REACTIONS: For athlete’s foot and ringworm - if irritation occurs or there is no improvement within 4 weeks. For prevention of athlete’s foot – if irritation occurs, discontinue use and consult a doctor.
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.